Overview
Datamonitor Healthcare interviewed two ulcerative colitis (UC) experts, one based in Italy and the other in the US, to gauge their views on approved and late-stage pipeline drugs, treatment challenges and unmet needs and the future treatment of UC. The specific drugs discussed include alicaforsen, Entyvio / vedolizumab [TKPYY], etrolizumab [RHHBF], filgotinib [GILD], Humira / adalimumab [ABBV], Inflectra / infliximab biosimilar, LT-02 [NSRGY], Ozanimod [CELG], Remicade / infliximab [JNJ], Simponi (SQ) / golimumab [JNJ], Stelara / ustekinumab [JNJ] and Xeljanz / tofacitinib [PFE]. The two interviews were combined into a single report.